ImClone declares freedom

ImClone declares freedom

ImClone Systems Inc. believes that last week's deal for its C225 cancer treatment with Merck KGaA frees it of dependency on the equity markets by providing enough funding - as much as $90 million in cash and loans - to reach

Read the full 448 word article

How to gain access

Continue reading with a
two-week free trial.